FDA Marketing Compliance: What Medical Device Companies Get Wrong

In 18 years of medical device marketing, I've reviewed thousands of pages of marketing copy, product pages, brochures, and social media posts. And I can tell you with certainty: most medical device companies are making compliance mistakes in their marketing materials right now. Some are minor. Some could trigger an FDA warning letter.

The frustrating part is that most of these mistakes are avoidable. They happen because marketing teams don't fully understand the regulatory framework, or because compliance review is treated as a bottleneck rather than an integrated part of the creative process. This guide covers the most common FDA marketing compliance mistakes I see and how to avoid them.

Why FDA Marketing Compliance Matters

The FDA regulates how medical device companies promote their products. This isn't advisory, it's enforceable law, which is exactly why FDA-compliant medical device marketing has to be built in from the first campaign, not bolted on after a warning letter. The consequences of non-compliance range from inconvenient to devastating:

• Warning letters. The most common enforcement action. Warning letters are public record, which means your customers, competitors, and investors can all see them. They require a formal response and corrective action within 15 business days.
• Product seizure. The FDA can seize products that are misbranded, meaning their labeling or promotional materials contain false or misleading claims.
• Injunctions. A court order that can prohibit the manufacture, distribution, or marketing of a device until compliance issues are resolved.
• Consent decrees. Binding legal agreements that impose strict conditions on future marketing activities, often including third-party oversight at the company's expense.
• Criminal prosecution. In serious cases, individuals responsible for violations can face criminal charges.

Beyond direct FDA enforcement, compliance failures damage credibility with the surgeons and hospital systems you're trying to sell to. A warning letter tells sophisticated healthcare buyers that you're either careless or dishonest with your product claims. Neither is a good look.

Recent FDA Warning Letter Trends: What 2024-2026 Enforcement Tells Us

FDA's Center for Devices and Radiological Health (CDRH) issues 30-50 warning letters per year that cite marketing or promotional violations. Reviewing the public warning letter database for the last 24 months reveals consistent patterns. Roughly two-thirds of marketing-related warning letters involve one of three recurring issues:

• Unsubstantiated efficacy claims. Companies promoting outcome statistics (success rates, cure rates, percentage reductions) without supporting clinical data in their cleared labeling. The FDA reads "92% of patients reported improvement" as a clinical efficacy claim regardless of whether it lives in a sales brochure, a website case study, or a 30-second LinkedIn video.
• Indication creep. Marketing materials that subtly broaden the indications beyond what was cleared. A device cleared for "treatment of moderate to severe symptoms in adults" promoted for "early intervention in mild cases" is off-label promotion, even when the language sounds innocuous.
• Implied superiority claims. Phrases like "the gold standard," "the most advanced," "industry-leading," or "next-generation" trigger FDA scrutiny when not supported by comparative clinical data. "Better" is a clinical claim that requires evidence.

One 2024 warning letter to a Class II device manufacturer cited 47 distinct promotional materials, website pages, brochures, social posts, conference abstracts, and sales scripts, each containing at least one violation. The corrective action plan required retrieval of printed materials from the field, archived snapshots of every webpage, and a third-party regulatory consultant overseeing future promotional review for 18 months. Estimated direct cost: north of $400,000, before considering lost sales velocity during the remediation window.

The lesson is simple: the FDA doesn't just review your homepage. When they open a promotional investigation, they pull everything in market, including content you forgot existed. (For deeper context, see our breakdown of recent FDA warning letters and the marketing lessons inside them.)

How the FDA Discovers Marketing Violations

Most warning letters don't originate from FDA-initiated surveillance. They start with:

• Competitor complaints. Competitors actively monitor each other and report perceived violations through FDA's online portal. If you're publishing aggressive marketing claims, assume your direct competitors are watching.
• Whistleblower reports. Former employees, departed sales reps, and clinical investigators frequently report compliance issues, sometimes for financial awards under federal whistleblower statutes.
• Inspection follow-ups. During routine 21 CFR 820 quality system inspections, FDA investigators often request copies of current promotional materials. Findings can flow into a separate promotional warning letter months later.
• MedWatch and PHSO tips. Patient and physician complaints filed through FDA's MedWatch system or the Public Health Service Office occasionally surface promotional issues alongside adverse event reports.

510(k) Cleared vs. FDA Approved: The Most Common Mistake

I estimate that 30-40% of medical device websites I audit use the phrase "FDA approved" incorrectly. This is the single most common compliance mistake in medical device marketing. (See the FDA-cleared vs FDA-approved glossary entry for the full distinction.)

Here's the distinction:

• 510(k) Clearance: The majority of medical devices reach the market through the 510(k) pathway. This requires demonstrating that the device is "substantially equivalent" to a predicate device already legally marketed in the United States. The result is FDA clearance, not approval.
• PMA (Premarket Approval): Reserved for Class III, high-risk devices like heart valves, implantable pacemakers, and certain orthopedic implants. PMA requires clinical trials demonstrating safety and effectiveness. This pathway results in FDA approval.

Writing "FDA approved" on your website when your device is 510(k) cleared is misbranding under federal law. It implies a level of regulatory scrutiny that your device has not undergone. The fix is simple: use "FDA 510(k) cleared" or simply "FDA cleared." But simple doesn't mean it's easy to catch across every page of your website, every sales deck, every trade show banner, and every social media post.

Promotional vs. Educational Content

The FDA draws a critical distinction between promotional content and educational content. Understanding this distinction shapes your entire content marketing strategy.

Promotional content is intended to promote the sale or use of a specific medical device. It must include specific required information: the device's cleared indications for use, relevant risk information, and a fair balance of benefits and risks. Promotional claims must be substantiated by adequate clinical evidence.

Educational content is intended to inform healthcare professionals or the public about diseases, conditions, or treatment options without promoting a specific product. Educational content has more latitude but must still be fair, balanced, and not misleading. It cannot be disguised promotion, if the primary purpose is to drive sales of your device, it's promotional regardless of how you label it.

The gray area between these categories is where most companies get into trouble. A "clinical education" webinar that exclusively features your device and is presented by a paid KOL may be viewed by the FDA as promotional, regardless of the educational wrapper.

Off-Label Promotion: The Bright Line

Off-label promotion is perhaps the most clearly defined boundary in medical device marketing. Your device was cleared for specific indications, specific uses, specific patient populations, specific anatomical locations. You cannot promote your device for any use outside those cleared indications.

Here's where it gets nuanced:

• Surgeons can use devices off-label. The FDA regulates manufacturers, not practitioners. A surgeon can use a device in any way they deem clinically appropriate. But you, the manufacturer, cannot encourage, suggest, or promote that off-label use.
• Responding to unsolicited questions. If a surgeon asks about an off-label use, you can provide truthful, balanced, non-misleading information in response. But you cannot proactively initiate the conversation, and the response should direct the surgeon to the device's approved labeling.
• Conference presentations. KOL presentations at medical conferences that discuss off-label uses of your device can be problematic if the company orchestrated the presentation, selected the speaker, or controlled the content. Independent scientific exchange is permissible; manufacturer-directed off-label promotion is not.
• Case studies. Publishing case studies that feature off-label uses requires careful handling. The line between scientific communication and promotion depends on context, distribution, and manufacturer involvement.

Clinical Claims and Evidence Requirements

Every claim you make about your medical device must be supported by evidence appropriate to the nature of the claim. This is where disciplined marketing teams separate themselves from everyone else.

Types of Claims and Their Evidence Requirements

• Safety claims require clinical data demonstrating the safety profile of your device for its cleared indications.
• Efficacy claims require clinical evidence, ideally from peer-reviewed studies, demonstrating that your device performs as claimed.
• Superiority claims (claiming your device is better than a competitor) require head-to-head comparative data. You cannot claim superiority based on anecdotal evidence or theoretical advantages.
• Equivalence claims (claiming comparable performance to a market-leading device) are safer but still require substantiation.

On a recent project with INFAB, our regulatory review identified three distinct categories of claims in the initial marketing copy that could not be adequately substantiated with available evidence. Rather than guessing, softening the language, or hoping nobody would notice, we flagged those claims as blocked items and routed them back to the client's regulatory and clinical teams for resolution. That's the discipline this work requires, you don't fill evidence gaps with creative writing.

Comparative Advertising

Medical device companies frequently want to compare their products to competitors. The FDA allows comparative advertising, but with strict guardrails:

• Comparisons must be truthful, not misleading, and substantiated by adequate evidence.
• You must compare comparable products, devices with similar indications, classifications, and risk profiles.
• Cherry-picking favorable data points while omitting unfavorable comparisons is misleading.
• Using a competitor's name requires that the comparison be fair and not disparaging beyond what the evidence supports.

The safest approach to competitive positioning is to clearly articulate your device's strengths with supporting evidence and let surgeons draw their own comparisons. Focus on what makes your device clinically differentiated rather than what's wrong with the competition.

Social Media and FDA Compliance

Social media creates unique compliance challenges for medical device companies. The FDA has issued guidance (final and draft) on social media, and the core principle is clear: FDA regulations apply regardless of the medium. We've written a detailed breakdown of social media marketing for medical devices that covers strategy alongside compliance.

Platform-Specific Considerations

• LinkedIn: The primary platform for medical device B2B marketing. Posts about products must include risk information and stay within cleared indications. Sharing clinical data requires the same evidentiary standards as any other promotional channel.
• Instagram and YouTube: Visual content featuring medical devices in clinical settings must not depict off-label uses. Video testimonials from surgeons must not include unsubstantiated claims.
• Character-limited platforms: Space constraints don't exempt you from required disclosures. If you can't include necessary risk and indication information within the platform's constraints, the FDA's position is that you shouldn't make the promotional claim on that platform.

User-Generated Content

When surgeons or patients comment on your social media posts with testimonials, off-label use descriptions, or unsubstantiated claims, you have a responsibility to manage that content. While the FDA doesn't hold manufacturers responsible for truly independent third-party content, content on your owned channels creates an implied endorsement that you need to actively manage.

Compliance for Sales Collateral, Trade Shows, and Reps

Most regulatory review processes focus on websites, blog posts, and digital ads. But FDA enforcement is just as aggressive against sales-channel content, and this is often where companies are most exposed because review cycles are looser.

• Sales decks and one-pagers. Every claim in a sales deck carries the same regulatory weight as a claim on your website. Most companies maintain decks that have evolved through 15 sales reps' edits, with claims added based on "what's working in the field." Audit them quarterly against your approved claims document.
• Trade show booth graphics. HIMSS, AAOS, RSNA, SAGES, AANS, every conference booth is a promotional display under FDA's interpretation. Large-format graphics, video loops, demo stations, and printed handouts all qualify as labeling and must include indications for use and balanced risk information.
• Sales rep talking points. What your reps say in the field is promotional speech. If they describe an off-label use, claim faster results than your labeling supports, or cherry-pick clinical outcomes, your company is liable. Document approved talking points, train against them, and require reps to route non-approved questions to medical affairs.
• Webinars and lunch-and-learns. Manufacturer-organized educational events featuring KOL speakers fall under promotional rules when the manufacturer controls slide content, speaker selection, or product framing. The FDA has issued multiple warning letters citing "scientific exchange" sessions that crossed into promotion.
• Conference abstracts and posters. Companies sponsoring research often share or distribute abstracts. If those abstracts contain off-label data or claims beyond cleared indications, distribution becomes promotion regardless of peer-review status.

The practical defense: maintain a single source-of-truth claims document. Every claim that has cleared regulatory review goes in this document with citation and approval date. Reps, agencies, and conference teams pull from this document only. If a claim isn't on the list, it's not approved. Re-audit the document before every major launch and at least quarterly otherwise.

Patient-Directed Advertising and Influencer Disclosures

Direct-to-consumer (DTC) medical device advertising, increasingly common as patients self-refer for elective procedures in aesthetics, orthopedics, and women's health, has its own compliance layer that sits on top of standard FDA rules.

• Restricted devices. Some devices have explicit DTC labeling requirements under 21 CFR. Promotional materials directed at patients must include adequate directions for use, contraindications, and major risk information.
• Patient testimonials. Patient stories used in marketing must be representative of typical results, not cherry-picked outliers. Both the FDA and FTC scrutinize "results not typical" disclaimers as insufficient when the testimonial itself implies otherwise.
• Before-and-after imagery. Common in aesthetic and surgical devices, before-and-after photos must accurately represent device performance under conditions of typical use. Heavily curated, ideal-case imagery raises FDA concerns about misleading promotion.
• Influencer partnerships. Paid social media partnerships with patient or HCP influencers must include both FTC material-connection disclosures (#ad, #sponsored) and FDA-compliant device information. The influencer's posts are treated as the manufacturer's promotional speech.
• "Find a doctor" tools. Healthcare provider locator features on company websites must not steer patients toward physicians selected primarily for aggressive prescribing patterns or off-label use of the device.

For aesthetic and surgical device companies running DTC campaigns, build a patient-facing review track in parallel to your HCP review track. The two audiences have different disclosure requirements, and copy that's fine for a surgeon often isn't fine for a patient.

How We Handle Regulatory Review at Buzzbox

At Buzzbox Media, regulatory compliance is integrated into our creative process, not bolted on at the end. Here's how we approach it:

1. Pre-screening during content creation. We use AI-assisted workflows to flag potential regulatory issues as content is being drafted. This catches obvious problems early, like "FDA approved" misuse, missing risk disclosures, or claims that extend beyond cleared indications.
2. Structured claim documentation. Every clinical claim in a piece of marketing content is documented with its supporting evidence. If we can't document the evidence, the claim doesn't make it into the copy.
3. Deliberate blocking. When we encounter claims that need clinical or regulatory input we don't have, we block those items and route them to the appropriate team rather than making assumptions. This was our approach on the INFAB project, where three categories of claims were deliberately excluded and flagged rather than estimated.
4. Human regulatory review. AI pre-screening catches the mechanical issues, but nuanced regulatory judgment requires human expertise. Every piece of promotional content gets reviewed by someone who understands the regulatory framework.

This process is slower than "write it and ship it." It's also the difference between marketing that builds credibility and marketing that generates warning letters.

10 Questions to Ask Before Publishing Medical Device Marketing Content

1. Is every reference to FDA status accurate (cleared vs. approved vs. granted)?
2. Do all promotional claims stay within the device's cleared indications for use?
3. Is every clinical claim supported by adequate, documented evidence?
4. Does the content include a fair balance of benefit and risk information?
5. Are any claims implied that aren't explicitly stated, and are those implied claims substantiated?
6. Does the content avoid promoting off-label uses, even indirectly?
7. If comparative claims are made, are they supported by head-to-head data?
8. For social media content, is required disclosure information included despite space limitations?
9. Has the content been reviewed by someone with regulatory expertise, not just marketing approval?
10. Would you be comfortable if the FDA reviewed this content tomorrow?

If you answered "no" or "I'm not sure" to any of these questions, the content needs more work before publication.

Regulatory compliance in medical device marketing isn't a constraint, it's a competitive advantage. Companies that get this right build credibility with surgeons, avoid costly enforcement actions, and create marketing that actually reflects the quality of their devices. If you need help building compliant marketing programs or want to learn more about how we integrate regulatory review into creative workflows, read our guide on AI in medical device marketing or get in touch.